CLINUVEL PHARMACEUTICALS

We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

CLINUVEL’s lead product, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In December 2014 the European Commission granted SCENESSE® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Latest Company Announcements

10 January 2018

Chair Letter to Shareholders

Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead.

Read More
21 December 2017

CLINUVEL Newsletter - December 2017

In the last communiqué of the calendar year, we take a breath and contemplate CLINUVEL’s status, a holding position for our teams over Christmas in the run up to a full 2018.

Read More
20 December 2017

Preliminary recommendation by NICE not to include SCENESSE® for reimbursement by NHS England

CLINUVEL PHARMACEUTICALS LTD today announced that the first draft assessment from England’s National Institute for Health and Care Excellence (NICE) has been published,

Read More
07 December 2017

CLINUVEL Newsletter - December 2017

The CLINUVEL team is looking with much optimism and energy to the start of 2018.

Read More
05 December 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
05 December 2017

Appendix 3Z - Final Director’s Interest Notice

Final Director’s Interest Notice

Read More

Quick Links